key: cord-0821819-xorb3wem
authors: Sterenczak, Katharina Anna; Barrantes, Israel; Stahnke, Thomas; Stachs, Oliver; Fuellen, Georg; Undre, Nasrullah
title: Co-infections: testing macrolides for added benefit in patients with COVID-19
date: 2020-11-02
journal: Lancet Microbe
DOI: 10.1016/s2666-5247(20)30170-1
sha: c9c09c866e048c5a47de8165d66daa4b317bd185
doc_id: 821819
cord_uid: xorb3wem

nan

AZT (sometimes also abbreviated AZM) is a macrolide antibiotic derived from erythromycin. It is indicated for mild to moderate infections caused by designated, susceptible bacteria, including community-acquired pneumonia (CAP) (of mild severity), pharyngitis/tonsillitis, skin infections, acute bacterial exacerbations of chronic bronchitis (mild to moderate), acute bacterial sinusitis, genital ulcer disease, as well as gonococcal and non-gonococcal urethritis and cervicitis. AZT is further used to treat cystic fibrosis, non-cystic fibrosis bronchiectasis, exacerbations of chronic obstructive pulmonary disease (COPD) and non-eosinophilic asthma. 1 These indications are corroborated by the Drugbank 2 entry that is based on the official drug label. AZT is approved and available globally and is on the World Health Organization's List of Essential Medicines, classified as critically important for human medicine. It is available under multiple brand names as generic medication. According to Drugbank, it "stops bacterial protein synthesis by inhibiting the transpeptidation/translocation step of protein synthesis and by inhibiting the assembly of the 50S ribosomal subunit". AZT binds to the 23S ribosomal RNA (rRNA) of the bacterial 50S ribosomal subunit.

JM is another macrolide antibiotic, produced by Streptomyces narbonensis var. josamyceticus (a variety of actinomycetes). 3 It is indicated for treatment of infections caused by susceptible Staphylococcus sp., Streptococcus sp., Streptococcus pneumoniae, Shigella sp., Haemophilus influenzae, and Mycoplasma sp. 4 JM was first approved in the 1970s and is in use in a number of countries. According to Drugbank, 2 its indication is "for the treatment of bacterial infections", further stating that "The anti-bacterial mechanism of action of macrolides such as JM is via inhibition of bacterial protein biosynthesis by binding reversibly to the subunit 50S of the bacterial ribosome, thereby inhibiting translocation of peptidyl tRNA. This action is mainly bacteriostatic, but can also be bactericidal in high concentrations. Macrolides tend to accumulate within leukocytes, and are therefore actually transported into the site of infection." Moreover, JM inhibits the bacterial ribosome more permanently than erythromycin. 5 More specifically, JM inhibits the peptidyl transferase reaction in particular in mitochondrial ribosomes, thereby blocking protein synthesis and decreasing mitochondrial DNA (mtDNA)-encoded protein levels, 6 and its action was modelled in detail based on structural data, suggesting a dual ribosome inhibitory action by direct inhibition of peptideelongation and also by indirect inhibition of peptide-elongation through rapid peptidyl-transfer RNA (tRNA) dropoff, leading to depletion of tRNA isoacceptors available for protein synthesis. 7

The in vitro anti-fibrotic effect of AZT was most recently described by Krempaska et al. 8 in a study using fibroblasts isolated from patients with Idiopathic Pulmonary Fibrosis (IPF-FB) and fibroblasts from normal subjects (control-FB). Fibroblasts were exposed to TGF-β (5 ng/ml), AZT (50 μM) or both, prior to gene expression analysis. Profibrotic gene expression was similarly reduced after AZT treatment in IPF and control-FB. Apoptosis was analyzed by flow cytometry, indicating that early apoptosis was significantly higher in TGF-β treated IPF-FB compared to control-FB after AZT. Further, AZT significantly reduced pro-fibrotic marker collagen Iα1 secretion in TGF-β treated IPF-FB compared to TGF-β treatment alone. 8 The immunomodulatory properties of AZT were recently reviewed by Zimmermann et al., 1 noting antiinflammatory properties of AZT in particular, which are in contrast to AZT's initial, stimulatory effects on immune and epithelial cells. 9 Finally, in vitro anti-viral activities of AZT have also been described. 10

When we compared in vitro data of gene-expression of fibrotic mechanisms triggered by TGF- in human tenon fibroblasts (believed to cause fibrosis after glaucoma surgery) to JM mechanisms in cancer cell lines, 11,12 interactions around cardiac muscle alpha actin 1 (ACTC1), interleukin-6 (IL-6) and CD34 that are typical of fibrosis were found to be counteracted by JM, 13 suggesting an anti-fibrotic repositioning of JM, which we could validate in vitro by measuring a reduction of α-smooth muscle actin (-SMA) and fibronectin. 13 In unpublished work, we also applied transcriptomics at time points 0, 1, 3, 6, 12, 24h after application of 150 ug JM to human tenon fibroblasts which were differentiated into fibrotic myofibroblasts by treatment with TGF-β. Clustering the genes by expression pattern using mfuzz 14 and subjecting the similarly regulated sets of genes to ontology and pathway analyses, we found patterns caused by ribosomal inhibition and xenobiotic response. We also found the upregulation of apoptosis, and the downregulation of metabolism, TGF- signalling, immune receptor signalling and proliferation, where the latter is back up at 24h. We also found a downregulation of all cyclin-dependent kinase inhibitors (CDKNs) at 24h (Sterenczak et al, unpublished). Cyclin-dependent kinase inhibitor (CDKN) downregulation is another hint at a potential senotherapeutic activity of JM. Notably, we repositioned JM based on downregulation of IL-6 and upregulation of CD34; 13 IL-6 is a strong and often-cited marker of adverse outcomes in COVID-19, 15 and in mouse models (based on bleomycin as well as infection), a protective role of CD34 in maintaining lung vascular integrity and restoring normal tissue architecture after injury was found. 16 Both IL-6 and CD34 were also associated to the glaucoma-related fibrosis by Yu-Wai-Man et al. 17 JM also induces apoptosis of human peripheral lymphocytes in vitro, presumably by the Fas-Fas ligand pathway, similarly to clarithromycin and AZT, in line with the observation that long-term administration of macrolides reduces the number of lymphocytes in bronchoalveolar lavage fluid of patients with chronic lower respiratory tract disease. 18 Thus, in principle, induction of apoptosis may contribute to a senolytic activity of JM.

Anti-inflammatory activity of JM is documented in murine macrophages after a lipopolysaccharide challenge, where it suppresses nuclear factor-kB (NF-kB) activation, IL-1b release, nitric oxide (NO) production (possibly due to heme oxygenase-1(HO-1) induction), and enhances suppressor of cytokine signalling (SOCS) (which suppresses inflammatory cytokine production). 19 Suppression of NO was also reported in rat pulmonary alveolar macrophages. 20 Further, JM suppresses the proliferation of human T cells by inhibiting IL-2 production 21 at concentrations of 1.6 to 40 ug/ml; regarding this effect it was more potent than clarithromycin. This fits with the observation that JM inhibits T helper type 1 (Th1) cells (characterized by cytokines IL-2, interferon γ (INF) and also Th2 (characterized by cytokines IL-4, IL-5, IL-6) cells in mouse skin after challenge. 1, 22 Finally, anti-viral effects of JM were described by Sugamata et al., 23 in mice infected with a lethal dose of A/H1N1 influenza virus. It was shown that JM was more effective than clarithromycin and an erythromycin derivative without antibacterial activity and that all compounds also inhibited virus proliferation in human pneumonia epithelial A549 cells in vitro.

Mechanistically, (chronic) inhibition of myeloperoxidase (MPO) release, of pro-inflammatory cytokines (of tumor necrosis factor α (TNF), IL-1a, monocyte chemoattractant protein 1 (MCP1), eotaxin, but not IL-6, granulocytemacrophage colony-stimulating factor (GM-CSF), macrophage inflammatory protein-1b (MIP-1b)), and of interferon- (IFN-α) production in the lung were described. 23 The "fibro-senolysis" hypothesis A major contributor to fibrosis are myofibroblasts, which are part of natural wound healing, but may stay active if this process cannot be resolved. Myofibroblasts are cells with a high metabolic rate that require energy for the synthesis and contraction of the extracellular matrix (ECM). According to Hinz & Lagares, 24 myofibroblasts "may evade apoptosis by activating molecular mechanisms in response to pro-survival biomechanical and growth factor signals from the fibrotic microenvironment, which can ultimately lead to the acquisition of a senescent phenotype", suggesting to target senescent myofibroblasts "for apoptosis with fibro-senolytic agents to reverse established fibrosis". Thus, we speculate that JM may inhibit highly metabolic senescent myofibroblasts, working as a senolytic just as AZT may do. 25 Most likely, temporal aspects of wound healing have to be considered when investigating the role of inflammation and senescence in fibrosis, and for both of which acute/initial and chronic/later phases can be distinguished. For example, the initial phase of cellular senescence may be reflected by the early SASP (senescenceassociated secretory phenotype, driven by NOTCH and TGF-) and it may promote fibrosis more directly (potentially, as part of a healing process), while its later phase reflected by the late senescence-associated secretory phenotype (SASP) coincides with chronic inflammation (marked by cytokines such as IL-6, etc.) and delayed wound healing. 26 SASP factors such as cellular communication network factor 1 (CCN1) and plasminogen activator inhibitor-1 (PAI-1) could play a major role in senescing myofibroblasts. 27

When administered as 2g extended release tablets, AZT achieved a mean Cmax of 0.72 µg/ml. AZT has a large volume of distribution (≈30 l/kg), suggesting extensive distribution into tissue. The mean plasma half-life of AZT is reported to be between 50 to 70 h which allows once daily administration. AZT is neither a substrate nor an inhibitor of cytochrome P450 3A4 (CYP3A4) and therefore, does not interact with medications that are metabolised by CYP3A4 or affected by inhibitors of CYP3A4. 9 After a single oral dose of 1 g, JM achieves a Cmax of 2.4 to 3 µg/ml. It penetrates well into tissue as judged by volume of distribution of 300 l. The half-life of Josamycin is usually reported to be roughly in the range 1 to 2 hours, and it thus requires twice daily administration. 28 AZT is concentrated in neutrophils, macrophages and particularly fibroblasts and thus fibroblasts may act as a reservoir for sustained release of AZT and for its transfer to neutrophils. 29 These observations are in concordance with the high abundance of JM in the lung after oral administration (for further pharmacokinetic data please see Table 1 , and specifically for the lung see Wildfeuer et al 30 ).

We are not the first to propose AZT as a seno-therapeutic for COVID-19, see Sargiacomo et al., 2020, 31 who moreover suggest that seno-therapy may also affect two host receptors for SARS-CoV-2, dipeptidyl peptidase-4 (CD26) and angiotensin-converting enzyme-2 (ACE-2), which are upregulated in senescent cells. In general, macrolides such as AZT and JM enable a multi-pronged approach, which needs to be evaluated in case of COVID-19. Their primary indication, which we also consider a necessary one, is their antibacterial effect. Second, there is ample evidence for their anti-inflammatory effect, specifically downregulating cytokines, as described above. Of note, high amounts of inflammation/cytokines tend to inhibit immunity. 32 Third, they may act in anti-fibrotic ways, as suggested above. Fourth, potentially related to their anti-fibrotic activity, their suspected inhibition or elimination of senescent cells may further reduce inflammation (by removing SASP signalling) and also prevent coagulation problems, 33, 34 which are frequently observed in cases of COVID-19. 35 Finally, as described above, they may even have an anti-viral effect. In conclusion, AZT and JM may be antibiotics of choice for COVID-19 patients. Bioavailability was significantly lower from the tablets than from the solution Please note: In studies* and ** an original abstract/publication was not available in online search; data herein presented were reported by 37 and 40 respectively

The Immunomodulatory Effects of Macrolides-A Systematic Review of the Underlying Mechanisms

DrugBank 5.0: a major update to the DrugBank database

Effect of mineral salts on apparent viscosity and a ratio of product components in josamycin fermentation

Macrolide antibiotics

Antibiotics and the ribosome

High-content screening for compounds that affect mtDNAencoded protein levels in eukaryotic cells

Cis-acting resistance peptides reveal dual ribosome inhibitory action of the macrolide josamycin

Azithromycin has enhanced effects on lung fibroblasts from idiopathic pulmonary fibrosis (IPF) patients compared to controls

Azithromycin: mechanisms of action and their relevance for clinical applications

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease

A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles

Suppression of the TGF-β pathway by a macrolide antibiotic decreases fibrotic responses by ocular fibroblasts in vitro

Mfuzz: a software package for soft clustering of microarray data

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Loss of Vascular CD34 Results in Increased Sensitivity to Lung Injury

Genome-wide RNA-Sequencing analysis identifies a distinct fibrosis gene signature in the conjunctiva after glaucoma surgery

Macrolide antibiotics induce apoptosis of human peripheral lymphocytes in vitro

Josamycin suppresses Prevotella intermedia lipopolysaccharideinduced production of nitric oxide and interleukin-1beta in murine macrophages

Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages

Immunomodulatory effects of three macrolides, midecamycin acetate, josamycin, and clarithromycin, on human T-lymphocyte function in vitro

Topical Application of Josamycin Inhibits Development of Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice

Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression

Evasion of apoptosis by myofibroblasts: a hallmark of fibrotic diseases

Azithromycin and Roxithromycin define a new family of "senolytic" drugs that target senescent human fibroblasts

Juxtacrine regulation of cellular senescence

Cellular senescence controls fibrosis in wound healing

Josamycin -das bessere Makrolid

Azithromycin in periodontal treatment: more than an antibiotic

COVID-19 and chronological aging: senolytics and other antiaging drugs for the treatment or prevention of corona virus infection?

Can blocking inflammation enhance immunity during aging?

Plasma proteomic signature of age in healthy humans

The Potential Role of Senescence As a Modulator of Platelets and Tumorigenesis

Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel

Use of josamycin in ophthalmology

Pharmacokinetics and clinical utilization of a new macrolide, josamycin

Pharmacokinetics of Josamycin -A New Macrolide Antibiotic

Comparative pharmacology of josamycin and erythromycin stearate

Distribution of josamycin in various human tissues

The penetration of macrolides into bronchial secretions

Pharmacokinetics of Josamycin in patients with liver cirrhosis and Gilbert's syndrome after repeated doses

Josamycin pulmonary penetration determined by broncho-alveolar lavage in man

Comparative bioavailability of josamycin, a macrolide antibiotic, from a tablet and solution and the influence of dissolution on in vivo release